Review Finds Civil Aviation Authorities' GLP-1 Guidance for Aircrew Diverges and Proposes Half-Life-Based Harmonized Protocol
Why It MattersInconsistent medical certification rules for aircrew on obesity drugs could complicate pilot and cabin-crew staffing across jurisdictions, and a harmonized standard would make crew medical eligibility more predictable internationally.
A narrative review published in Cureus compares how civil aviation authorities in the United States, the United Kingdom, the European Union, New Zealand, Australia and Canada handle glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in aircrew. The drugs covered include tirzepatide, a dual agonist, and the oral agents semaglutide and orforglipron. The authors note that these drugs are increasingly prescribed for obesity, a condition common among airline pilots.

The review finds that authorities now accept these drugs in aircrew, but their guidance differs and has not been compared with the pharmacology of each agent. Half-lives range from two to three days for orforglipron to about one week for semaglutide, so exposure approaches steady state between one and five weeks after each dose change. Gastrointestinal adverse events are frequent and cluster during dose escalation, while acute kidney injury, pancreatitis and gallbladder disease may also occur later in treatment.
Observation periods in current guidance range from one to four weeks after initiation and from 48 hours to five days after a dose increase, and none of the guidance documents stated a pharmacokinetic basis for them. The Federal Aviation Administration halved its observation period after initiation within one year. No authority addressed reinitiation after missed doses, and only one explicitly covered cabin crew. The European Union Aviation Safety Agency has not published common guidance on these drugs for obesity, leaving national authorities to adopt their own procedures.
The authors propose a phase-based protocol in which stand-down periods follow each agent's half-life: four weeks after initiation and seven days after each dose increase for the weekly agents, and two weeks and three days, respectively, for orforglipron. A multi-pilot limitation would apply until the maintenance dose reaches steady state, followed by periodic review of weight, heart rate, blood pressure and symptoms. Specific rules would address missed doses, switches between agents or formulations, and cabin crew.

















































